INTRODUCTION: Empiric data on indirect (herd) effects of pneumococcal conjugate vaccines (PCVs) in settings with low or heterogeneous PCV coverage are limited. The indirect effects of PCV, which benefits both vaccinated and non-vaccinated individuals, are mediated by reductions in vaccine-type (VT) carriage (a prerequisite for disease). The aim of this study among hospitalised children in Lao People's Democratic Republic (Lao PDR) is to determine the effectiveness of a 13-valent PCV (PCV13) against VT pneumococcal nasopharyngeal carriage (direct effects) and the association between village-level PCV13 coverage and VT carriage (indirect effects). METHODS: Pneumococcal nasopharyngeal carriage surveillance commenced in December 2013, shortly a...
BACKGROUND: Nasopharyngeal carriage of Streptococcus pneumoniae precedes disease, is the source of p...
Background: Pneumococcal pneumonia is a leading cause of childhood mortality. Pneumococcal conjugate...
Background Cambodia introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in January 2015 ...
International audienceIntroduction: Empiric data on indirect (herd) effects of pneumococcal conjugat...
Introduction Empiric data on indirect (herd) effects of pneumococcal conjugate vaccines (PCVs) in se...
INTRODUCTION: Empiric data on indirect (herd) effects of pneumococcal conjugate vaccines (PCVs) in s...
Pneumococcal carriage is a prerequisite for disease, and underpins herd protection provided by pneum...
INTRODUCTION: Pneumococcal conjugate vaccines (PCVs) prevent disease through both direct protection ...
Background: Within Ulaanbaatar, Mongolia, risk factors for pneumonia are concentrated among children...
© 2021 Jocelyn Yuen-Wai ChanPneumococcal disease is a leading cause of childhood morbidity and morta...
OBJECTIVES: Pneumococcal conjugate vaccines (PCVs) are effective in reducing pneumococcal disease. W...
Objectives: Pneumococcal conjugate vaccines (PCVs) are effective in reducing pneumococcal disease. W...
Background: Pneumococcal disease is an important cause of childhood morbidity and mortality worldwid...
Background Cambodia introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in January 2015...
Background: Within Ulaanbaatar, Mongolia, risk factors for pneumonia are concentrated among children...
BACKGROUND: Nasopharyngeal carriage of Streptococcus pneumoniae precedes disease, is the source of p...
Background: Pneumococcal pneumonia is a leading cause of childhood mortality. Pneumococcal conjugate...
Background Cambodia introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in January 2015 ...
International audienceIntroduction: Empiric data on indirect (herd) effects of pneumococcal conjugat...
Introduction Empiric data on indirect (herd) effects of pneumococcal conjugate vaccines (PCVs) in se...
INTRODUCTION: Empiric data on indirect (herd) effects of pneumococcal conjugate vaccines (PCVs) in s...
Pneumococcal carriage is a prerequisite for disease, and underpins herd protection provided by pneum...
INTRODUCTION: Pneumococcal conjugate vaccines (PCVs) prevent disease through both direct protection ...
Background: Within Ulaanbaatar, Mongolia, risk factors for pneumonia are concentrated among children...
© 2021 Jocelyn Yuen-Wai ChanPneumococcal disease is a leading cause of childhood morbidity and morta...
OBJECTIVES: Pneumococcal conjugate vaccines (PCVs) are effective in reducing pneumococcal disease. W...
Objectives: Pneumococcal conjugate vaccines (PCVs) are effective in reducing pneumococcal disease. W...
Background: Pneumococcal disease is an important cause of childhood morbidity and mortality worldwid...
Background Cambodia introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in January 2015...
Background: Within Ulaanbaatar, Mongolia, risk factors for pneumonia are concentrated among children...
BACKGROUND: Nasopharyngeal carriage of Streptococcus pneumoniae precedes disease, is the source of p...
Background: Pneumococcal pneumonia is a leading cause of childhood mortality. Pneumococcal conjugate...
Background Cambodia introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in January 2015 ...